Raj has over 20 years’ experience in identifying, nurturing and partnering early stage technologies and spin-out companies. He was part-time interim CEO of GammaDelta Therapeutics prior to joining full time as Director of Intellectual Property, Alliance Management and Business Development. In addition to GammaDelta Therapeutics, Raj has led on formation and has been interim CEO and board member of BliNK Therapeutics and Revitope. Prior to joining GammaDelta Therapeutics, Raj led portfolio management and commercialisation of oncology focused therapeutic and diagnostic assets at Cancer Research Technology.